CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Explore how volatility affects retirees in index funds and what tactics—like rebalancing and withdrawal rules—can help manage risk.
23,516 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Large XRP holders appear to be withdrawing from selling on major exchanges even as market volatility persists. With B...
Two streaming giants are pulling in opposite directions in 2026. Netflix has stumbled, while Roku gains traction. Thi...
SpaceX's public debut ignites a rapid sector rotation out of listed space stocks. Virgin Galactic craters 24% as inve...
As AI infrastructure names retreat from spring highs, June market conditions and resilient AI demand are prompting in...
AI excitement has investors chasing the next big thing. Yet a cautionary line attributed to Sam Altman still echoes i...
Ford investors are watching for signs of real momentum beyond headlines. This article breaks down the latest little g...
Two very different consumer stocks sit at the crossroads of retail: American Eagle Outfitters and Chewy. This analysi...
Markets are waiting for the actual reopening of the Strait of Hormuz, and the real deciders may be the shipping fleet...
As Micron gears up for its June earnings, a fresh investing angle centers on the idea that prediction: micron stock w...
PepsiCo stock faces a potential move toward $180 as analysts cite World Cup-driven demand, cost cuts, and internation...
Global markets are buzzing as offshore crypto platforms increasingly offer pre-IPO exposure tied to SpaceX rumors. Tr...